Alimta for Mesothelioma FAQs Is Alimta chemo or immunotherapy
Poster Session II - RECOVERY, REHABILITATION AND OUTCOME 03.00 - RECOVERY, REHABILITATION AND OUTCOME - 03.01 - REHABILITATION P832 - ESOC25-1295 POST-STROKE FACIAL PALSY: PREVALENCE ON ADMISSION, RISK FACTORS, AND RECOVERY WITH HYPER-ACUTE TREATMENTS Zewen Lu 1 , Havva Eroglu 2 , Halvor Nss 3 , Matthew Gittins 1 , Amit Kishore 4 , Craig Smith 5 , Andy Vail 1 , Claire Mitchell 2 1 Centre for Biostatistics, University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom, 2 Division of Psychology, Communication & Human Neuroscience, Geoffrey Jefferson Brain Research Centre, University of Manchester, Manchester, United Kingdom, 3 Department of Neurology, University of Bergen, Haukeland University Hospital, Bergen, Norway, 4 Division of Cardiovascular Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, United Kingdom, 5 Division of Cardiovascular Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, Manchester, United Kingdom Background and Aims: Facial palsy affects 40 - 50% of stroke survivors, impacting quality of life, communication, and emotional expression
Facile fabrication of redox nanoparticles loaded with exosomal-miRNAs and resveratrol as glycation inhibitor in alleviating the progression and development of diabetic cataract
Cell Host Microbe
However, although numerous studies of DTP cells have extensively outlined the details of resistance mechanisms, many directions of research into the DTP cells in AML remain to be pursued
